Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors

被引:0
作者
Fatma Ilknur Cinar
Muhammet Cinar
Sedat Yilmaz
Ismail Simsek
Hakan Erdem
Salih Pay
机构
[1] Gulhane Military Medical Academy,School of Nursing
[2] Gulhane Military Medical Academy,Division of Rheumatology, School of Medicine
来源
Rheumatology International | 2014年 / 34卷
关键词
Ankylosing spondylitis; Anti-TNF-α therapy; Patients’ perceptions;
D O I
暂无
中图分类号
学科分类号
摘要
The risk of infections and malignancies is the major area of concern with anti-tumor necrosis factor (anti-TNF) agents. The aim of this study was to investigate patients’ views about their treatments and the factors that influence patients’ treatment decisions concerning the use of anti-TNF-α drugs. This descriptive study was conducted in a single rheumatology unit. Patients using anti-TNF-α drugs for at least 3 months were included. Patients’ thoughts and perceptions about their treatment were evaluated using a questionnaire. A total of 101 (94.1 % male) patients were recruited. The patients described their feelings as hopeful, worried, happy, scared, desperate, and hopeless, with the order decreasing beginning with the first. Hope for healing and an expectation of increased quality of life were the most significant determinants for acceptance of treatment. After the drug information was given, patients described their feelings as follows: increase in anxiety, psychologically wearisome, and worrying about their condition worsening in the future. After anti-TNF-α treatment, patients described their experience as follows: “the most effective medicine that I have ever used,” “it saved my life,” “control procedures that were carried out before the treatment and once every 3 months after the treatment were essential,” “I feel myself safe with these controls,” and “I advised other people.” This study, to our knowledge, is the first to evaluate the attitudes of patients concerning anti-TNF-α drugs from the stage of informed consent to the post-experience stage. We found that standard consent forms caused an increase in the level of anxiety among new users of anti-TNF-α drugs, although the aim was the exact opposite. The reasons for acceptance were the hope for healing, reliance on physicians, and advice of other patients. Most patients accepted follow-up control procedures, which aimed to diagnose adverse effects early.
引用
收藏
页码:979 / 986
页数:7
相关论文
共 224 条
  • [1] Farren W(2013)Fatigue in ankylosing spondylitis: causes, consequences and self-management Musculoskelet Care 11 39-50
  • [2] Goodacre L(2005)Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study Ann Rheum Dis 64 1568-1575
  • [3] Stigant M(2012)Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level Rheumatol Int 32 323-330
  • [4] Marzo-Ortega H(2009)‘It’s magic stuff’: the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication Musculoskelet Care 7 162-177
  • [5] McGonagle D(2011)Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial Ann Rheum Dis 70 590-596
  • [6] Jarrett S(2009)Effectiveness, safety, and predictors of good clinical response in 1,250 patients treated with adalimumab for active ankylosing spondylitis J Rheumatol 36 801-808
  • [7] Haugeberg G(2009)Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis Arthr Rheum 60 946-954
  • [8] Hensor E(2005)Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis Ann Rheum Dis 64 229-234
  • [9] O’Connor P(2003)International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis 62 817-824
  • [10] Tan AL(2004)Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis Ann Rheum Dis 63 1594-1600